Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

PHASE4CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Constipation
Interventions
DRUG

Lubiprostone

12 mcg capsule once daily (QD)

DRUG

Lubiprostone

12 mcg capsule twice daily (BID)

DRUG

Lubiprostone

24 mcg capsule twice daily (BID)

Trial Locations (19)

17604

Regional Gastroenterology Associates of Lancaster, Ltd., Lancaster

32207

Nemours Children's Clinic - Jacksonville, Jacksonville

32504

Nemours Children's Clinic - Pensacola, Pensacola

37403

Southeastern Clinical Research, Chattanooga

38305

Jackson Clinic, Jackson

43205

Children's Research Institute, Columbus

45014

Pediatric Associates of Fairfield, Inc., Fairfield

46202

Indiana University, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

60068

Center for Children's Digestive Health, Park Ridge

61613

University of Illinois at Peoria, Peoria

66160

University of Kansas Medical Center, Kansas City

68105

The Center for Human Nutrition, Inc., Omaha

72005

Arkansas Pediatric Clinic, Little Rock

85016

Phoenix Children's Hospital, Phoenix

94609

Children's Hospital and Research Center Oakland, Oakland

62708-0787

University of Illinois at Chicago, Springfield

02115

Children's Hospital Boston, Boston

07962

AHS Hospital Corporation, Morristown

All Listed Sponsors
collaborator

Sucampo Pharmaceuticals, Inc.

INDUSTRY

lead

Sucampo Pharma Americas, LLC

INDUSTRY

NCT00452335 - Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation | Biotech Hunter | Biotech Hunter